Clinical Trials Browser

Phase 2 × Neoplasms × ruxolitinib × Clear all

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Phase 2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

Clinical Trials

INCB018424 in Patients With Advanced Hematologic Malignancies

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies